Trial Profile
A Study to Evaluate the Benefit/Risk Perception of Natalizumab Therapy in Neurologists and Their Patients with Relapsing Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERCEPT
- 09 Dec 2015 New trial record